Skip to main content
Premium Trial:

Request an Annual Quote

Core Life Sciences to Distribute Biogazelle qPCR Software in California

Premium

Core Life Sciences said today that it has partnered with Belgium's Biogazelle to distribute its qbase+ qPCR software in California.

Based on geNorm and qBase technology developed by Ghent University's Jo Vandesompele and Jan Hellemans, qbase+ is qPCR data-analysis software designed for mRNA gene expression profiling and analysis, miRNA profiling and validation studies, and gene copy number analysis, among other applications.

The software provides "fast, flexible, and reliable qPCR analysis in an open format, with integrated proprietary algorithms and features that have been published in peer-reviewed journals," Core Life Sciences said in a statement.

In addition, qbase+ enables data normalization, quality control, and inter-run calibration, allowing users to "easily generate publication-ready results," the company said. The software is also compliant with the minimum information for publication of quantitative real-time PCR experiment (MIQE) guidelines.

Based in Laguna Niguel, Calif., Core Life Sciences is a distributor and service provider for microarray, PCR, electrophoresis, and microplate products for life science research.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.